Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis

Alessandro Fichera, Nathaniel Little, Sujatha Jagadeeswaran, Urszula Dougherty, Amikar Sehdev, Reba Mustafi, Sonia Cerda, Weihua Yuan, Sharad Khare, Maria Tretiakova, Can Gong, Michael Tallerico, Greg Cohen, Loren Joseph, John Hart, Jerrold R. Turner, Marc Bissonnette

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Colonic carcinogenesis involves the progressive dysregulation of homeostatic mechanisms that control growth. The epidermal growth factor (EGF) receptor (EGFR) regulates colonocyte growth and differentiation and is overexpressed in many human colon cancers. A requirement for EGFR in colonic premalignancy, however, has not been shown. In the current study, we used a specific EGFR antagonist, gefitinib, to investigate this role of the receptor in azoxymethane colonic premalignancy. The azoxymethane model shares many clinical, histologic, and molecular features of human colon cancer. Mice received azoxymethane i.p. (5 mg/kg/wk) or saline for 6 weeks. Animals were also gavaged with gefitinib (10 mg/kg body weight) or vehicle (DMSO) thrice weekly for 18 weeks, a dose schedule that inhibited normal receptor activation by exogenous EGF. Compared with control colonocytes [bromodeoxyuridine (BrdUrd), 2.2 ± 1.2%], azoxymethane significantly increased proliferation (BrdUrd, 12.6 ± 2.8%), whereas gefitinib inhibited this hyperproliferation (BrdUrd, 6.2 ± 4.0%; <0.005). Azoxymethane significantly induced pro-transforming growth factor-α. (6.4 ± 1.3-fold) and increased phospho(active) EGFR (5.9 ± 1.1-fold), phospho-(active) ErbB2 (2.3 ± 0.2-fold), and phospho-(active) extracellular signal-regulated kinase (3.3 ± 0.4-fold) in premalignant colonocytes. Gefitinib inhibited activations of these kinases by >75% (P < 0.05). Gefitinib also significantly reduced the number of large aberrant crypt foci and decreased the incidence of colonic microadenomas from 75% to 33% (P < 0.05). Gefitinib concomitantly decreased cell cycle-regulating cyclin D1 and prostanoid biosynthetic enzyme cyclooxygenase-2 in microadenomas, suggesting that these regulators are key targets of EGFR in colonic carcinogenesis. These results show for the first time that EGFR signaling is required for early stages of colonic carcinogenesis. Our findings suggest, moreover, that inhibitors of EGFR might be useful in chemopreventive strategies in individuals at increased risk for colonic malignancies.

Original languageEnglish (US)
Pages (from-to)827-835
Number of pages9
JournalCancer Research
Volume67
Issue number2
DOIs
StatePublished - Jan 15 2007

Fingerprint

Azoxymethane
Epidermal Growth Factor Receptor
Carcinogenesis
Bromodeoxyuridine
Colonic Neoplasms
Aberrant Crypt Foci
Cyclin D1
Cyclooxygenase 2
Growth
Dimethyl Sulfoxide
Epidermal Growth Factor
Prostaglandins
Appointments and Schedules
Cell Cycle
Body Weight
gefitinib
Incidence
Enzymes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. / Fichera, Alessandro; Little, Nathaniel; Jagadeeswaran, Sujatha; Dougherty, Urszula; Sehdev, Amikar; Mustafi, Reba; Cerda, Sonia; Yuan, Weihua; Khare, Sharad; Tretiakova, Maria; Gong, Can; Tallerico, Michael; Cohen, Greg; Joseph, Loren; Hart, John; Turner, Jerrold R.; Bissonnette, Marc.

In: Cancer Research, Vol. 67, No. 2, 15.01.2007, p. 827-835.

Research output: Contribution to journalArticle

Fichera, A, Little, N, Jagadeeswaran, S, Dougherty, U, Sehdev, A, Mustafi, R, Cerda, S, Yuan, W, Khare, S, Tretiakova, M, Gong, C, Tallerico, M, Cohen, G, Joseph, L, Hart, J, Turner, JR & Bissonnette, M 2007, 'Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis', Cancer Research, vol. 67, no. 2, pp. 827-835. https://doi.org/10.1158/0008-5472.CAN-05-3343
Fichera, Alessandro ; Little, Nathaniel ; Jagadeeswaran, Sujatha ; Dougherty, Urszula ; Sehdev, Amikar ; Mustafi, Reba ; Cerda, Sonia ; Yuan, Weihua ; Khare, Sharad ; Tretiakova, Maria ; Gong, Can ; Tallerico, Michael ; Cohen, Greg ; Joseph, Loren ; Hart, John ; Turner, Jerrold R. ; Bissonnette, Marc. / Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. In: Cancer Research. 2007 ; Vol. 67, No. 2. pp. 827-835.
@article{5becb354536e425891f55812a91312fe,
title = "Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis",
abstract = "Colonic carcinogenesis involves the progressive dysregulation of homeostatic mechanisms that control growth. The epidermal growth factor (EGF) receptor (EGFR) regulates colonocyte growth and differentiation and is overexpressed in many human colon cancers. A requirement for EGFR in colonic premalignancy, however, has not been shown. In the current study, we used a specific EGFR antagonist, gefitinib, to investigate this role of the receptor in azoxymethane colonic premalignancy. The azoxymethane model shares many clinical, histologic, and molecular features of human colon cancer. Mice received azoxymethane i.p. (5 mg/kg/wk) or saline for 6 weeks. Animals were also gavaged with gefitinib (10 mg/kg body weight) or vehicle (DMSO) thrice weekly for 18 weeks, a dose schedule that inhibited normal receptor activation by exogenous EGF. Compared with control colonocytes [bromodeoxyuridine (BrdUrd), 2.2 ± 1.2{\%}], azoxymethane significantly increased proliferation (BrdUrd, 12.6 ± 2.8{\%}), whereas gefitinib inhibited this hyperproliferation (BrdUrd, 6.2 ± 4.0{\%}; <0.005). Azoxymethane significantly induced pro-transforming growth factor-α. (6.4 ± 1.3-fold) and increased phospho(active) EGFR (5.9 ± 1.1-fold), phospho-(active) ErbB2 (2.3 ± 0.2-fold), and phospho-(active) extracellular signal-regulated kinase (3.3 ± 0.4-fold) in premalignant colonocytes. Gefitinib inhibited activations of these kinases by >75{\%} (P < 0.05). Gefitinib also significantly reduced the number of large aberrant crypt foci and decreased the incidence of colonic microadenomas from 75{\%} to 33{\%} (P < 0.05). Gefitinib concomitantly decreased cell cycle-regulating cyclin D1 and prostanoid biosynthetic enzyme cyclooxygenase-2 in microadenomas, suggesting that these regulators are key targets of EGFR in colonic carcinogenesis. These results show for the first time that EGFR signaling is required for early stages of colonic carcinogenesis. Our findings suggest, moreover, that inhibitors of EGFR might be useful in chemopreventive strategies in individuals at increased risk for colonic malignancies.",
author = "Alessandro Fichera and Nathaniel Little and Sujatha Jagadeeswaran and Urszula Dougherty and Amikar Sehdev and Reba Mustafi and Sonia Cerda and Weihua Yuan and Sharad Khare and Maria Tretiakova and Can Gong and Michael Tallerico and Greg Cohen and Loren Joseph and John Hart and Turner, {Jerrold R.} and Marc Bissonnette",
year = "2007",
month = "1",
day = "15",
doi = "10.1158/0008-5472.CAN-05-3343",
language = "English (US)",
volume = "67",
pages = "827--835",
journal = "Cancer Research",
issn = "0008-5472",
number = "2",

}

TY - JOUR

T1 - Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis

AU - Fichera, Alessandro

AU - Little, Nathaniel

AU - Jagadeeswaran, Sujatha

AU - Dougherty, Urszula

AU - Sehdev, Amikar

AU - Mustafi, Reba

AU - Cerda, Sonia

AU - Yuan, Weihua

AU - Khare, Sharad

AU - Tretiakova, Maria

AU - Gong, Can

AU - Tallerico, Michael

AU - Cohen, Greg

AU - Joseph, Loren

AU - Hart, John

AU - Turner, Jerrold R.

AU - Bissonnette, Marc

PY - 2007/1/15

Y1 - 2007/1/15

N2 - Colonic carcinogenesis involves the progressive dysregulation of homeostatic mechanisms that control growth. The epidermal growth factor (EGF) receptor (EGFR) regulates colonocyte growth and differentiation and is overexpressed in many human colon cancers. A requirement for EGFR in colonic premalignancy, however, has not been shown. In the current study, we used a specific EGFR antagonist, gefitinib, to investigate this role of the receptor in azoxymethane colonic premalignancy. The azoxymethane model shares many clinical, histologic, and molecular features of human colon cancer. Mice received azoxymethane i.p. (5 mg/kg/wk) or saline for 6 weeks. Animals were also gavaged with gefitinib (10 mg/kg body weight) or vehicle (DMSO) thrice weekly for 18 weeks, a dose schedule that inhibited normal receptor activation by exogenous EGF. Compared with control colonocytes [bromodeoxyuridine (BrdUrd), 2.2 ± 1.2%], azoxymethane significantly increased proliferation (BrdUrd, 12.6 ± 2.8%), whereas gefitinib inhibited this hyperproliferation (BrdUrd, 6.2 ± 4.0%; <0.005). Azoxymethane significantly induced pro-transforming growth factor-α. (6.4 ± 1.3-fold) and increased phospho(active) EGFR (5.9 ± 1.1-fold), phospho-(active) ErbB2 (2.3 ± 0.2-fold), and phospho-(active) extracellular signal-regulated kinase (3.3 ± 0.4-fold) in premalignant colonocytes. Gefitinib inhibited activations of these kinases by >75% (P < 0.05). Gefitinib also significantly reduced the number of large aberrant crypt foci and decreased the incidence of colonic microadenomas from 75% to 33% (P < 0.05). Gefitinib concomitantly decreased cell cycle-regulating cyclin D1 and prostanoid biosynthetic enzyme cyclooxygenase-2 in microadenomas, suggesting that these regulators are key targets of EGFR in colonic carcinogenesis. These results show for the first time that EGFR signaling is required for early stages of colonic carcinogenesis. Our findings suggest, moreover, that inhibitors of EGFR might be useful in chemopreventive strategies in individuals at increased risk for colonic malignancies.

AB - Colonic carcinogenesis involves the progressive dysregulation of homeostatic mechanisms that control growth. The epidermal growth factor (EGF) receptor (EGFR) regulates colonocyte growth and differentiation and is overexpressed in many human colon cancers. A requirement for EGFR in colonic premalignancy, however, has not been shown. In the current study, we used a specific EGFR antagonist, gefitinib, to investigate this role of the receptor in azoxymethane colonic premalignancy. The azoxymethane model shares many clinical, histologic, and molecular features of human colon cancer. Mice received azoxymethane i.p. (5 mg/kg/wk) or saline for 6 weeks. Animals were also gavaged with gefitinib (10 mg/kg body weight) or vehicle (DMSO) thrice weekly for 18 weeks, a dose schedule that inhibited normal receptor activation by exogenous EGF. Compared with control colonocytes [bromodeoxyuridine (BrdUrd), 2.2 ± 1.2%], azoxymethane significantly increased proliferation (BrdUrd, 12.6 ± 2.8%), whereas gefitinib inhibited this hyperproliferation (BrdUrd, 6.2 ± 4.0%; <0.005). Azoxymethane significantly induced pro-transforming growth factor-α. (6.4 ± 1.3-fold) and increased phospho(active) EGFR (5.9 ± 1.1-fold), phospho-(active) ErbB2 (2.3 ± 0.2-fold), and phospho-(active) extracellular signal-regulated kinase (3.3 ± 0.4-fold) in premalignant colonocytes. Gefitinib inhibited activations of these kinases by >75% (P < 0.05). Gefitinib also significantly reduced the number of large aberrant crypt foci and decreased the incidence of colonic microadenomas from 75% to 33% (P < 0.05). Gefitinib concomitantly decreased cell cycle-regulating cyclin D1 and prostanoid biosynthetic enzyme cyclooxygenase-2 in microadenomas, suggesting that these regulators are key targets of EGFR in colonic carcinogenesis. These results show for the first time that EGFR signaling is required for early stages of colonic carcinogenesis. Our findings suggest, moreover, that inhibitors of EGFR might be useful in chemopreventive strategies in individuals at increased risk for colonic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=33846659399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846659399&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-3343

DO - 10.1158/0008-5472.CAN-05-3343

M3 - Article

C2 - 17234795

AN - SCOPUS:33846659399

VL - 67

SP - 827

EP - 835

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 2

ER -